Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands
20 juin 2019 08h30 HE
|
Celsion CORP
An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range...
Celsion Corporation Reports First Quarter 2019 Financial Results and Provides Business Update
15 mai 2019 08h00 HE
|
Celsion CORP
Company to Hold Conference Call on Wednesday, May 15, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J, May 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug...
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
08 mai 2019 17h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
Celsion Corporation Announces Issuance of New Patent for ThermoDox®
17 avr. 2019 08h00 HE
|
Celsion CORP
Represents a Significant Advance for Celsion’s Life Cycle Management Program for ThermoDox® Establishing Bioequivalence Will Extend Market Exclusivity to 2033 LAWRENCEVILLE, N.J,...
Celsion Corporation to Participate in Two Investor Conferences in May 2019
12 avr. 2019 08h30 HE
|
Celsion CORP
Company to Discuss its Ongoing Pivotal Phase III Study in Primary Liver Cancer and its Phase I/II Clinical Study in Ovarian Cancer LAWRENCEVILLE, N.J., April 12, 2019 (GLOBE NEWSWIRE) -- Celsion...
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
12 avr. 2019 08h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., April 12, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
Celsion Corporation Reports 2018 Financial Results
29 mars 2019 08h00 HE
|
Celsion CORP
Celsion Enters 2019 with a Strong Balance Sheet, Clean Capitalization Structure and an Advancing Clinical Pipeline Company to Hold Conference Call on Friday, March 29, 2019 at 11:00 a.m. EDT ...
Celsion Corporation to Hold Year-End 2018 Financial Results Conference Call on Friday, March 29, 2019
22 mars 2019 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J, March 22, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended...
Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
04 mars 2019 08h30 HE
|
Celsion CORP
100% Objective Response Rates and 88% Complete (R0) Resection Rates in Highest Dose Cohorts GEN-1 Intraperitoneally Delivered Durable Local Levels of Pro-Immune IL-12 and Related Cytokines ...
Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
21 févr. 2019 16h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on February 19, 2019, the Compensation Committee...